TPC-1 Cells

The TPC-1 cell line originates from a papillary thyroid carcinoma (PTC) and is widely utilized as a model for studying the molecular mechanisms of thyroid cancer. This cell line is notable for harboring the RET/PTC1 rearrangement, a hallmark genetic alteration in PTC. The RET/PTC1 fusion results in constitutive activation of RET tyrosine kinase signaling, driving oncogenic processes such as increased cellular proliferation, survival, and differentiation. This genetic feature has made TPC-1 a valuable tool in understanding thyroid oncogenesis and in evaluating targeted therapies. Derived from a well-differentiated thyroid tumor, TPC-1 retains epithelial characteristics and exhibits features associated with thyroid differentiation, including thyroglobulin production. TPC-1 has been extensively studied for its signaling pathways, particularly the MAPK and PI3K/AKT pathways, which are activated downstream of RET/PTC1. These pathways are critical to thyroid tumor progression and represent targets for therapeutic intervention. In addition to its genetic and cellular characteristics, TPC-1 has been employed in in vitro and in vivo models to investigate the effectiveness of RET inhibitors and other targeted therapies. Its well-characterized genetic background and responsiveness to pharmacological agents make it a crucial model for translational research in thyroid cancer. Studies comparing TPC-1 with other thyroid cancer cell lines have also highlighted its role in identifying common and distinct molecular features of thyroid cancer subtypes, aiding in the development of personalized treatment strategies. Head-Neck cancer cell lines, Thyroid, Thyroid gland papillary carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1